Archived Webcasts
AmeirsourceBergen Specialty Group has archived selected presentations to provide instant access to industry information, forecasts and guidance. Click on the topic below to access previous webcasts. Or to view our list of current, live webcasts, click here
Change is Coming to Healthcare, But When?
Analysis and Predictions on the Obama Administration's Plans for Healthcare Reform
Originally broadcast: March 03, 2009
In recent weeks, the headlines have screamed with news of the deepening recession, partisan battles over a national economic stimulus package and the failed nomination of Tom Daschle as secretary of Health and Human Services. All this may have altered the Obama administration’s timeline for overhauling the U.S. healthcare system, but the President and the 111th Congress continue to view comprehensive health reform as a high priority.
View this on-demand webcast, which explores health policy changes to-date, likely initiatives for President Obama and the Democratic-controlled Congress, as well as the impact these initiatives may have on manufacturers, payers, physicians and patients.
Our panel of policy experts provide a lively discussion that addresses:
- Early indicators and steps toward healthcare reform under the Obama administration
- Potential for Medicare reform in 2009
- Will the White House or Congress lead comprehensive reform?
Moderator
Peyton Howell, MHA
President, Consulting Services & Health Policy
AmerisourceBergen Specialty Group
Speakers
Fred Graefe, J.D.
Law Office of Frederick Graefe, PLLC
Rita Norton
Vice President, Government Affairs
AmerisourceBergen Corp.
Sarah Walter, J.D.
Walter Consulting
The New Compendia Landscape: Reimbursement changes to expect and anticipated impact on manufacturers
Originally broadcast: December 10, 2008
Drug compendia reflect more than the clinical value of pharmaceutical products. Because the Centers for Medicare and Medicaid Services (CMS) require coverage of compendia-listed off-label drug uses, the compendia are also tied intrinsically to the products’ financial value. Changes to compendia can significantly impact a product’s success—positively or negatively. The good news is manufacturers don’t have to be merely spectators to these changes.
View an archived webcast that explores the recent and key modifications to CMS’ utilization of the compendia, the effect these changes could have on manufacturers and how manufacturers can be active participants in the process. Peyton Howell of AmerisourceBergen Specialty Group and Loreen Brown of Xcenda discuss:
- The role compendia play in coverage decisions
- An overview of the compendia review processes and rating systems
- How the recent changes affect Medicare, Medicaid and private payers
- Results from payer market research regarding compendia utilization
Moderator:
Peyton Howell, MHA
President, Consulting Services & Health Policy
AmerisourceBergen Specialty Group
Presenter:
Loreen Brown, MSW
Senior Director, Xcenda
Self-administered v. Provider-administered: How route of administration in oncology products affects payer coverage and product strategy
Originally broadcast: August 28, 2008
Self-administered oncology products are changing the treatment paradigm. Where patients once received treatment exclusively in the physician office or hospital setting, many patients can now receive treatment virtually anywhere. This shift could have a substantial impact across all stakeholders: pharmaceutical manufacturers, providers, patients and payers.
View this online discussion that explores how route of therapy administration influences product success, reimbursement and patient access.
Learning Objectives
Dr. Joel Schwartz, chief of hematology/oncology for North Shore Medical Center, and Dr. Michael Fine, medical director for Health Net, will provide insight into critical questions facing the oncology market:
- What are the key issues and concerns for providers, payers and patients?
- How do coverage policies influence treatment preferences of oncologists?
- How has drug coverage evolved in the public and private payer markets?
- How are managed care organizations evaluating oncology agents for formulary consideration?
Moderator
Gina K. Clark
Senior Vice President, Business Solutions
AmerisourceBergen Specialty Group
Presenters
Joel H. Schwartz, MD, FACP
Chief of Hematology/Oncology
North Shore Medical Center
Michael Fine, MD
Medical Director
Health Net
Alternative Distribution Solutions: Examining distribution strategies to address dynamic product needs and market changes
Originally broadcast: July 31, 2008
Manufacturers report a need for increased cost-efficiencies in this financially conscious environment. They want flexibility to support multiple distribution channels and improved access to actionable data. At the same time, regulatory and other market challenges have caused them to take a closer look at how they distribute their products.
Join us on July 31 at 2:00 PM (EASTERN) for an interactive webcast that examines how alternative and custom distribution solutions have helped many manufacturers confront these substantial issues.
Learning Objectives
- Understand how supply constraints, diversion concerns, REMS requirements, pedigree legislation and a host of other issues impact a manufacturer’s ability to distribute products to the end customer
- Gain insight into manufacturer needs for support of multiple distribution channels
- Learn the types of data available to manufacturers and the implications this data has on product strategy
- See case study examples of manufacturers that have already put alternative distribution strategies in place and the results they have experienced
Moderator
Peyton Howell
President, Pharma & Specialty Services
AmerisourceBergen Specialty Group
Presenters
David Cheetham
President
ICS
Doug Cook
Vice President, Client Services
ICS
Wheels of Change in Washington: How Presidential Candidates, Congress and CMS May Impact Patient Support Services
Originally broadcast: June 26, 2008
Along with the war in Iraq and the economy, healthcare has become a crucial, hot-button issue for the presidential candidates. Though their approaches to healthcare reform differ dramatically in many areas, the candidates share a common promise—change. Depending on which candidate emerges victorious, what does this change actually mean for pharmaceutical manufacturers and for the healthcare industry as a whole? And how do legislative and Medicare changes continue to influence patient care?
Discover how the presidential candidates, Congress and CMS may impact patient support services through the remainder of the year and beyond. View our on-demand webcast “Wheels of Change in Washington."
Is Patient Compliance Your Next Blockbuster Drug?
Originally broadcast: May 28, 2008
Pharmaceutical manufacturers spend billions of dollars each year on the research and development that will produce their next successful product. But in the wake of stagnant development pipelines and growing competition from generics, many manufacturers are taking a closer look at patient compliance as a way to drive product success and boost financial results. Join us for an in-depth Webcast that provides insight on how compliance rates affect clinical outcomes, market perception and product revenue—as well as what manufacturers can do about it.
Jan Nielsen of ICS and Mike Eaddy of Xcenda (both companies of AmerisourceBergen Specialty Group) will present analysis and case examples that will allow attendees to learn more about:
- Market conditions that make patient compliance more important than ever
- The impact that non-compliance can have on patient results and how that affects the real-world image and effectiveness of products
- How and why patients remain compliant with prescribed therapy
- How pharmaceutical companies can accurately measure patient compliance to understand the size of their opportunities
- Case examples of how selected manufacturers have increased compliance and enhanced product success
Featured Speakers
Jan Nielsen, RN, MPA
Vice President, Clinical Services
ICS
Mike Eaddy, PharmD, PhD
Senior Director
Comparative Effectiveness: Emerging use with public and private payers and potential impact on manufacturers
Originally broadcast: May 20, 2008
Rising costs pose a significant challenge to the U.S. healthcare system. Congress, public and private payers and other stakeholders have growing interest in using comparative effectiveness research to control costs and support value-based purchasing. Policymakers continue to examine the framework for this research at the national level. Additionally, private payers have already begun comparing the effectiveness of products. Widespread use of comparative effectiveness data could have profound implications for manufacturers as well as the entire healthcare system.
Learning Objectives:
- Understand the definition and scope of comparative effectiveness
- Gain insight into current comparative effectiveness research efforts
- See analysis of recent legislative and policy developments
- Discover potential implications of comparative effectiveness research on manufacturers and other stakeholders
- Identify strategies and considerations for navigating the comparative effectiveness landscape
- Learn methods for implementing comparative effectiveness research
Moderator:
Peyton Howell, M.H.A., President, Pharma & Specialty Services, AmerisourceBergen Specialty Group
Presenters:
Grant Bagley, M.D., J.D., Partner, HillCo Partners
Thomas Bramley, R.Ph., Ph.D., Senior Director, Xcenda
Gene Reeder, R.Ph., Ph.D., Director, Xcenda
Market Value Plan (MVP): A comprehensive approach to developing a product value proposition and reimbursement strategy
Originally broadcast: April 29, 2008
Several external factors have impacted the way pharmaceutical manufacturers commercialize their products and compete in the marketplace. Increasing payer influence, pressure from generic entries and greater focus on comparative product effectiveness all demand that products have sound value propositions. Additionally, the switch from development of traditional, small molecule products to specialty products has expanded the set of reimbursement challenges. These market dynamics have forced brand managers to change their approach to brand planning and product strategy. This case-based webcast presents a comprehensive approach to addressing these issues and developing a sound product value proposition.
Presenters:
Sigrid Schreiner, MHA, CMPE, Vice President, Xcenda (View Bio)
Matt Sarnes, PharmD, Executive Director, Xcenda (View Bio)
Medicare Part D's Impact on Patient Assistance Programs
Originally broadcast: June 14, 2007
View a free, informative Webcast featuring the latest on this complex federal program
Pharmaceutical companies rely on patient assistance programs as an essential strategy for maintaining accessibility to vital drugs. But now, in the world of Medicare Part D, these same assistance programs can present unprecedented complexities. Join us for an in-depth Webcast that explores Medicare Part D’s influence on patients, the concerns and requirements of federal agencies and solutions for manufacturers.
Presenter: Tracy Foster, MBA, President, Lash Group
